Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T22:19:06.957Z.
Calculation as of: 2026-10-06T22:19:06.957Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e8daa83f2db5fafa0746e2d75675d68491b64c400a2027f88c30977eae97731f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$344.04M
EV/Sales Ratio
N/A
TTM Avg
102877.97x
3Y Avg
102877.97x
5Y Avg
102877.97x
Market Cap
$349.70M
EV/Sales Ratio
12.51x
TTM Avg
33.06x
3Y Avg
53.36x
5Y Avg
138.77x
Market Cap
$353.88M
EV/Sales Ratio
5.76x
TTM Avg
7.29x
3Y Avg
5.92x
5Y Avg
7.97x
Market Cap
$355.36M
EV/Sales Ratio
1.18x
TTM Avg
1.33x
3Y Avg
1.47x
5Y Avg
1.68x
Market Cap
$355.43M
EV/Sales Ratio
N/A
TTM Avg
50.09x
3Y Avg
50.09x
5Y Avg
50.09x
Market Cap
$359.53M
EV/Sales Ratio
5.37x
TTM Avg
5.77x
3Y Avg
8.21x
5Y Avg
104.30x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | $346.73M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | N/A | 102877.97x | 102877.97x | 102877.97x |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | 12.51x | 33.06x | 53.36x | 138.77x |
| Ocugen, Inc. (OCGN)vs › | $352.67M | 74.37x | 97.80x | 57.72x | 64.32x |
| Embecta Corp. (EMBC)vs › | $353.00M | 1.61x | 1.60x | 1.83x | 2.04x |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | 5.76x | 7.29x | 5.92x | 7.97x |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 1.18x | 1.33x | 1.47x | 1.68x |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | N/A | 50.09x | 50.09x | 50.09x |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | 5.37x | 5.77x | 8.21x | 104.30x |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | 31.23x | 114.38x | 98.11x | 98.11x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
